DE60035697D1 - Screening nach verbindungen, die tgf-beta abhängige zellsignale modifizieren können - Google Patents

Screening nach verbindungen, die tgf-beta abhängige zellsignale modifizieren können

Info

Publication number
DE60035697D1
DE60035697D1 DE60035697T DE60035697T DE60035697D1 DE 60035697 D1 DE60035697 D1 DE 60035697D1 DE 60035697 T DE60035697 T DE 60035697T DE 60035697 T DE60035697 T DE 60035697T DE 60035697 D1 DE60035697 D1 DE 60035697D1
Authority
DE
Germany
Prior art keywords
tgf
agents
screening
compounds
dependent cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60035697T
Other languages
English (en)
Other versions
DE60035697T2 (de
Inventor
Merl F Hoekstra
Weilin Xie
Brion W Murray
Frank M Mercurio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signal Pharmaceuticals LLC
Original Assignee
Signal Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharmaceuticals LLC filed Critical Signal Pharmaceuticals LLC
Publication of DE60035697D1 publication Critical patent/DE60035697D1/de
Application granted granted Critical
Publication of DE60035697T2 publication Critical patent/DE60035697T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60035697T 1999-08-30 2000-08-29 Screening nach verbindungen, die tgf-beta abhängige zellsignale modifizieren können Expired - Fee Related DE60035697T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/385,918 US7358056B1 (en) 1999-08-30 1999-08-30 Methods for modulating signal transduction mediated by TGF-β and related proteins
US385918 1999-08-30
PCT/US2000/023729 WO2001016604A1 (en) 1999-08-30 2000-08-29 Screening for agents modulating tgf-beta cell signaling

Publications (2)

Publication Number Publication Date
DE60035697D1 true DE60035697D1 (de) 2007-09-06
DE60035697T2 DE60035697T2 (de) 2008-04-30

Family

ID=23523429

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60035697T Expired - Fee Related DE60035697T2 (de) 1999-08-30 2000-08-29 Screening nach verbindungen, die tgf-beta abhängige zellsignale modifizieren können

Country Status (8)

Country Link
US (2) US7358056B1 (de)
EP (2) EP1918716A2 (de)
JP (1) JP2003508755A (de)
AT (1) ATE368227T1 (de)
AU (1) AU781152B2 (de)
CA (1) CA2383514A1 (de)
DE (1) DE60035697T2 (de)
WO (1) WO2001016604A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846746B2 (en) * 2001-04-10 2010-12-07 Children's Medical Center Corporation Methods of analysis and labeling of protein-protein interactions
US20030012818A1 (en) * 2001-04-25 2003-01-16 Eidgenossische Technische Hochschule Zurich And Universitat Zurich Drug delivery matrices to enhance wound healing
RU2322984C2 (ru) * 2001-10-05 2008-04-27 Комбинаторкс, Инкорпорейтед Комбинации для лечения иммуновоспалительных расстройств
GB0302315D0 (en) * 2003-02-01 2003-03-05 Univ East Anglia Novel therapeutic target
EP3059245B1 (de) * 2004-07-23 2018-11-07 Acceleron Pharma Inc. Actrii-rezeptor antagonistische antikörper
US20100183514A1 (en) * 2007-05-29 2010-07-22 President And Fellows Of Harvard College Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof
WO2011088163A1 (en) 2010-01-14 2011-07-21 President And Fellows Of Harvard College Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
GB201013284D0 (en) * 2010-08-06 2010-09-22 Isogenica Ltd Scaffold peptides
PL2981822T4 (pl) 2013-05-06 2021-07-12 Scholar Rock, Inc. Kompozycje i sposoby modulacji czynnika wzrostu
CN103558395B (zh) * 2013-10-28 2015-08-26 深圳市第二人民医院 Smad3基因在检测上尿路上皮癌中的应用
KR101683544B1 (ko) * 2014-12-19 2016-12-08 한양대학교 산학협력단 탈인산화 또는 인산화 효소 활성 검출용 조성물 및 검출 방법
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
JP2022532216A (ja) * 2019-05-15 2022-07-13 シンセックス， インコーポレイテッド タンパク質の選択的分解

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001619A (en) 1995-10-04 1999-12-14 Cold Spring Harbor Laboratory Ubiquitin ligases, and uses related thereto
US6011137A (en) * 1996-04-03 2000-01-04 University Of North Carolina At Chapel Hill Identification and isolation of novel polypeptides having WW domains and methods of using same
AU741242B2 (en) 1997-05-20 2001-11-29 Ludwig Institute For Cancer Research Smad2 phosphorylation and interaction with Smad4
WO1999001765A1 (en) 1997-07-01 1999-01-14 Sloan Kettering Institute For Cancer Research METHODS OF INHIBITING OR ENHANCING THE TGFβ-SMAD SIGNALING PATHWAY
US6060262A (en) 1997-07-16 2000-05-09 Mitotix, Inc. Regulation of I Kappa B (IκB) degradation and methods and reagents related thereto
US5976849A (en) * 1998-02-05 1999-11-02 Zeneca Limited Human E3 ubiquitin protein ligase
JP2003502064A (ja) 1999-06-11 2003-01-21 ザ リサーチ ファウンデーション オブ ステイト ユニバーシティー オブ ニューヨーク ＢＭＰおよびＴＧＦβシグナル伝達経路のアンタゴニスト

Also Published As

Publication number Publication date
US7358056B1 (en) 2008-04-15
EP1212621A1 (de) 2002-06-12
ATE368227T1 (de) 2007-08-15
EP1918716A2 (de) 2008-05-07
JP2003508755A (ja) 2003-03-04
DE60035697T2 (de) 2008-04-30
WO2001016604A1 (en) 2001-03-08
EP1212621B1 (de) 2007-07-25
AU781152B2 (en) 2005-05-12
AU7086600A (en) 2001-03-26
US20030119072A1 (en) 2003-06-26
CA2383514A1 (en) 2001-03-08

Similar Documents

Publication Publication Date Title
DE60035697D1 (de) Screening nach verbindungen, die tgf-beta abhängige zellsignale modifizieren können
DE59611411D1 (de) Verwendung von alpha 1l-agonisten zur behandlung der harninkontinenz
PT934325E (pt) Trisanidridos biciclicos de tetrafosfonato
ATE337021T1 (de) Anordnungen, systeme und verfahren zur behandlung von biologischen flüssigkeiten mit licht
MX339420B (es) Compuestos para la modulacion de la actividad de ppar gamma.
ATE353640T1 (de) Antagoniste zur behandlung von cd11/cd18 adhäsionsrezeptor-vermittelten krankheiten
BR8802492A (pt) Composicao esterilizante e de alto grau desinfetante,inodora
ATE413386T1 (de) Ppar-gamma modulatoren
DE60029812D1 (de) Diagnose von zellenproliferation sowie screeningverfahren für deren modulatore
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
ATE255632T1 (de) Immortalisierung bzw. desimmortalisierung von zellen
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
DE69940206D1 (de) Verfahren zur behandlung von multiplem myelom und von myelom- induzierter knochenresorption mit antagonisten der integrin-/rezeptorbindung
ES2193919T3 (es) Inhibidores de la enzima convertidora de endotelina.
DE69934595D1 (de) Verwendung von verbindungen die alpha2-antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle
DE69425820D1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
ATE259818T1 (de) Substituierte tricyclische verbindungen und deren verwendung zur behandlung von spla2-bedingten erkrankungen
DE69939723D1 (de) Verwendung von Intereferon Gamma zur Behandlung von Herzhypertrophie
DE3856329D1 (de) Verwendung von Ethisterone zur topischen Behandlung von Akne oder androgenetischer Alopezie
DE69834937D1 (de) Antibiotika zur behandlung von magengeschwuren
ES2063004T3 (es) Antibioticos ab-006 y procedimiento para su produccion.
DE60034779D1 (de) Insulinartiger-wachstumsfaktorbindungsprotein-4-protease
ATE288498T1 (de) Methoden zur inhibierung von helicobacter pylori
ATE431399T1 (de) Verwendung von cytokinen, zellen und mitogene zur hemmung der graft-versus-host krankheit
DE69409961D1 (de) Triarylethylenderivate zur therapeutischen verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee